Microbot Medical Inc (NASDAQ: MBOT) has seen a decline in its stock price by -0.73 in relation to its previous close of 1.39. However, the company has experienced a -2.13% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-04 that Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year
Is It Worth Investing in Microbot Medical Inc (NASDAQ: MBOT) Right Now?
Additionally, the 36-month beta value for MBOT is 1.47. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MBOT is 30.96M and currently, short sellers hold a 15.36% ratio of that float. The average trading volume of MBOT on March 07, 2025 was 4.15M shares.
MBOT’s Market Performance
The stock of Microbot Medical Inc (MBOT) has seen a -2.13% decrease in the past week, with a -32.36% drop in the past month, and a 36.62% gain in the past quarter. The volatility ratio for the week is 8.93%, and the volatility levels for the past 30 days are at 10.38% for MBOT. The simple moving average for the last 20 days is -20.19% for MBOT stock, with a simple moving average of 17.03% for the last 200 days.
Analysts’ Opinion of MBOT
Many brokerage firms have already submitted their reports for MBOT stocks, with H.C. Wainwright repeating the rating for MBOT by listing it as a “Buy.” The predicted price for MBOT in the upcoming period, according to H.C. Wainwright is $26 based on the research report published on January 13, 2020 of the previous year 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MBOT reach a price target of $12, previously predicting the price at $10. The rating they have provided for MBOT stocks is “Buy” according to the report published on December 24th, 2019.
Ladenburg Thalmann gave a rating of “Buy” to MBOT, setting the target price at $1.75 in the report published on January 31st of the previous year.
MBOT Trading at -21.14% from the 50-Day Moving Average
After a stumble in the market that brought MBOT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.17% of loss for the given period.
Volatility was left at 10.38%, however, over the last 30 days, the volatility rate increased by 8.93%, as shares sank -37.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +40.07% upper at present.
During the last 5 trading sessions, MBOT fell by -3.19%, which changed the moving average for the period of 200-days by +45.20% in comparison to the 20-day moving average, which settled at $1.7283. In addition, Microbot Medical Inc saw 23.21% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MBOT
Current profitability levels for the company are sitting at:
- -72.27 for the present operating margin
- 0.46 for the gross margin
The net margin for Microbot Medical Inc stands at -78.91. The total capital return value is set at -2.67. Equity return is now at value -200.70, with -158.98 for asset returns.
Based on Microbot Medical Inc (MBOT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -95.29. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -155.5.
Currently, EBITDA for the company is -10.63 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 332.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.64.
Conclusion
In conclusion, Microbot Medical Inc (MBOT) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
